Nature Communications, Published online: 03 June 2026; doi:10.1038/s41467-026-73546-7 A molecular alteration, MYOD1L122R, predicts poor prognosis for patients with rhabdomyosarcoma. Here, the authors demonstrate that this mutation increases cancer stem cell frequency via upregulation of ROR2, identifying a therapeutic target in preclinical models of MYOD1L122R rhabdomyosarcoma.